Interleukin-6 in Rheumatoid Arthritis

Franco Pandolfi, Laura Franza, Valentina Carusi, Simona Altamura, Gloria Andriollo, Eleonora Nucera

Research output: Contribution to journalReview articlepeer-review


The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.

Original languageEnglish
JournalInt J Mol Sci
Issue number15
Publication statusPublished - Jul 23 2020


  • Antibodies, Monoclonal/pharmacology
  • Arthritis, Rheumatoid/drug therapy
  • Disease Progression
  • Humans
  • Interleukin-6/antagonists & inhibitors
  • Molecular Targeted Therapy
  • Signal Transduction/drug effects


Dive into the research topics of 'Interleukin-6 in Rheumatoid Arthritis'. Together they form a unique fingerprint.

Cite this